At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 24 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 750
- Started
- 2025-02-13
- Last checked
- 2025-03
Plain English Summary
What is this study?
- • Testing a new treatment for liver cirrhosis
- • Clinical study - 750 participants
- • Liver cancer is often diagnosed too late for effective treatment
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with liver cirrhosis
Where?
- • London - Imperial College London
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Liver cancer is often diagnosed too late for effective treatment. The VOCAL2 study is developing a simple, non-invasive breath test to help detect liver cancer earlier and monitor liver conditions like cirrhosis. The test analyzes tiny chemicals in exhaled breath called volatile organic compounds (VOCs) to identify signs of liver disease. Who can take part? Adults aged 18 or older who: Have liver cancer (hepatocellular carcinoma or cholangiocarcinoma), or Have liver cirrhosis or primary sclerosing cholangitis, or Have tummy symptoms but a normal liver scan. What's involved? Participants will: Give a breath sample after fasting for 6 hours. Answer a few health questions. Allow access to relevant medical records. The appointment lasts about 1 hour at an NHS hospital. Benefits \& Risks This research could lead to an earlier, easier way to detect liver cancer, but there's no direct health benefit for participants. There are no risks, as breath sampling is completely non-invasive and safe. Where is the study happening? Led by Imperial College London, running in NHS hospitals across the UK. Who is funding the study? The study is funded by Rosetrees and Stoneygate Trust. Contact Information Email: vocal-study@imperial.ac.uk Phone: +44 (0)20 7594 3396
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Males and females
- ✓Adult participants ≥ 18 years old
- ✓Participants with either:
- ✓Histologically or radiologically-confirmed\* hepatocellular carcinoma or cholangiocarcinoma (participants with liver...
- ✓Liver cirrhosis, confirmed on imaging or histology from biopsy (participants with benign liver disorders)
Who cannot take part
- ✗Active infection, or receiving immunosuppressive medications, within the preceding eight weeks
- ✗History of another cancer within the previous five years
- ✗Previous liver resection
- ✗Already received drug treatment, radiotherapy or surgery for their liver cancer
- ✗other health conditions preventing breath collection
See the full criteria
Where Is This Study? (1 UK site)
Imperial College London
London, United Kingdom
How to Get in Touch
Georgios Karagiannidis, MBBS(Hon)
Sponsor contactCONTACT